Abiopharma

🔍 Epstein Jeffrey Douglas (Executive)

Company: RRE Ventures Acquisition Corp. (RREV)

Report Date: 2026-03-02

Detailed Transactions and Holdings:

• Acquired 450,000 shares of Class B Ordinary Shares (Derivative)
  Date: 2026-03-02 | Code: A | equity_swap_involved: false | shares_owned_after: 450,000.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F2
• Acquired 150,000 shares of Class B Ordinary Shares (Derivative)
  Date: 2026-03-18 | Code: A | equity_swap_involved: false | shares_owned_after: 600,000.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F2
• Acquired 500,000 shares of Warrant at $11.5 per share (Derivative)
  Date: 2026-05-01 | Code: A | equity_swap_involved: false | shares_owned_after: 500,000.00 | transaction_form_type: 4 | Footnotes: F3, F3

Footnotes:

• F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date.
• F2: These securities were previously reported on a Form 3 filed by the Reporting Person.
• F3: The private placement warrants will become exercisable 30 days after the completion of the Issuer's initial business combination and will expire five years after the completion of the Issuer's initial business combination or earlier upon liquidation.